This year’s Drugs to Watch™ report identifies seven late-stage experimental treatments that Clarivate analysts forecast to reach blockbuster status within five years, i.e., if approved, are expected to earn $1 billion in annual revenue. These treatments span a diverse set of therapeutic areas, from conditions like Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM), to very rare diseases, such as transthyretin amyloidosis (ATTR).
Access this webinar to learn more about the future blockbusters.
Additionally, we have a spotlight on key areas of therapeutic innovation such as RNA treatments, CRISPR-Cas9, oncolytics and machine learning (ML) for drug discovery and their potential to transform patient outcomes and drug landscape.
We have also covered the generics landscape with information around key branded drugs losing exclusivity in 2021.
Lastly, we have provided a summary of vaccines and treatments for COVID-19 which manufacturers have brought to the market with emergency or full authorization.